Mast Group Launches New ESPLINE SARS-CoV-2 Lateral Flow Antigen Test
By HospiMedica International staff writers
Posted on 26 Nov 2020
Mast Group Ltd. (Liverpool, UK) has launched the new ESPLINE SARS-CoV-2 lateral flow antigen test for the detection of COVID-19.Posted on 26 Nov 2020
The ESPLINE SARS-CoV-2 is an immunochromographic assay for the detection of SARS-CoV-2 antigen directly from nasopharyngeal swab. The lateral flow test is to be used as an aid in the diagnosis of SARS-CoV-2 infection. ESPLINE SARS-CoV-2 is a cassette-style assay using a simple procedure without any special instruments. As a feature, the test kit utilizes several kinds of antibodies to capture protein insideSARS-CoV-2 and coloring method based on enzyme reaction to detect the antigen-antibody complex.
Image: ESPLINE SARS-CoV-2 lateral flow antigen test (Photo courtesy of Mast Group Ltd.)
The test kit shows test result within 30 minutes after the reaction begins (positive results: 10-30 minutes, negative results: 30 minutes). The ESPLINE SARS-CoV-2 lateral flow antigen test has a sensitivity of 80% and specificity of 100%.
Related Links:
Mast Group Ltd.
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Cannulating Sphincterotome
TRUEtome
New
Hospital Data Analytics Software
OR Companion
